Literature DB >> 19339477

Evaluation of smallpox vaccines using variola neutralization.

Inger K Damon1, Whitni B Davidson1, Christine M Hughes1, Victoria A Olson1, Scott K Smith1, Robert C Holman1, Sharon E Frey2, Frances Newman2, Robert B Belshe2, Lihan Yan3, Kevin Karem1.   

Abstract

The search for a 'third'-generation smallpox vaccine has resulted in the development and characterization of several vaccine candidates. A significant barrier to acceptance is the absence of challenge models showing induction of correlates of protective immunity against variola virus. In this light, virus neutralization provides one of few experimental methods to show specific 'in vitro' activity of vaccines against variola virus. Here, we provide characterization of the ability of a modified vaccinia virus Ankara vaccine to induce variola virus-neutralizing antibodies, and we provide comparison with the neutralization elicited by standard Dryvax vaccination.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19339477      PMCID： PMC2887573          DOI： 10.1099/vir.0.010553-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN： 0022-1317            Impact factor:   3.891


  21 in total

1.  Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence.

Authors:  H Meyer; G Sutter; A Mayr
Journal:  J Gen Virol       Date:  1991-05       Impact factor: 3.891

2.  Prevalence of antibodies to Vaccinia virus after smallpox vaccination in Italy.

Authors:  Mike M Pütz; Isabella Alberini; Claire M Midgley; Ilaria Manini; Emanuele Montomoli; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2005-11       Impact factor: 3.891

3.  Activity of vaccinia virus-neutralizing antibody in the sera of smallpox vaccinees.

Authors:  Kendra M Viner; Stuart N Isaacs
Journal:  Microbes Infect       Date:  2005-03-22       Impact factor: 2.700

4.  Proteome-wide analysis of the serological response to vaccinia and smallpox.

Authors:  D Huw Davies; Douglas M Molina; Jens Wrammert; Joe Miller; Siddiqua Hirst; Yunxiang Mu; Jozelyn Pablo; Berkay Unal; Rie Nakajima-Sasaki; Xiaowu Liang; Shane Crotty; Kevin L Karem; Inger K Damon; Rafi Ahmed; Luis Villarreal; Philip L Felgner
Journal:  Proteomics       Date:  2007-05       Impact factor: 3.984

Review 5.  The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses.

Authors:  G Antoine; F Scheiflinger; F Dorner; F G Falkner
Journal:  Virology       Date:  1998-05-10       Impact factor: 3.616

6.  characterization of acute-phase humoral immunity to monkeypox: use of immunoglobulin M enzyme-linked immunosorbent assay for detection of monkeypox infection during the 2003 North American outbreak.

Authors:  Kevin L Karem; Mary Reynolds; Zach Braden; Gin Lou; Nikeva Bernard; Joanne Patton; Inger K Damon
Journal:  Clin Diagn Lab Immunol       Date:  2005-07

Review 7.  Adverse events occurring after smallpox vaccination.

Authors:  J Michael Lane; Joel Goldstein
Journal:  Semin Pediatr Infect Dis       Date:  2003-07

Review 8.  Correlates of protective immunity in poxvirus infection: where does antibody stand?

Authors:  Vijay Panchanathan; Geeta Chaudhri; Gunasegaran Karupiah
Journal:  Immunol Cell Biol       Date:  2007-10-09       Impact factor: 5.126

9.  Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge.

Authors:  Sharon E Frey; Frances K Newman; Jeffrey S Kennedy; Vera Sobek; Francis A Ennis; Heather Hill; Lihan K Yan; Paul Chaplin; Jens Vollmar; Bernard R Chaitman; Robert B Belshe
Journal:  Vaccine       Date:  2007-10-26       Impact factor: 3.641

10.  Response to smallpox vaccine in persons immunized in the distant past.

Authors:  Sharon E Frey; Frances K Newman; Lihan Yan; Kathleen R Lottenbach; Robert B Belshe
Journal:  JAMA       Date:  2003-06-25       Impact factor: 56.272
View more
  19 in total

1.  Analysis of variola and vaccinia virus neutralization assays for smallpox vaccines.

Authors:  Christine M Hughes; Frances K Newman; Whitni B Davidson; Victoria A Olson; Scott K Smith; Robert C Holman; Lihan Yan; Sharon E Frey; Robert B Belshe; Kevin L Karem; Inger K Damon
Journal:  Clin Vaccine Immunol       Date:  2012-05-16

2.  Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration.

Authors:  Marissa B Wilck; Michael S Seaman; Lindsey R Baden; Stephen R Walsh; Lauren E Grandpre; Colleen Devoy; Ayush Giri; Jane A Kleinjan; Lizanne C Noble; Kristen E Stevenson; Haesook T Kim; Raphael Dolin
Journal:  J Infect Dis       Date:  2010-05-01       Impact factor: 5.226

3.  Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals.

Authors:  Sharon E Frey; Patricia L Winokur; Heather Hill; Johannes B Goll; Paul Chaplin; Robert B Belshe
Journal:  Vaccine       Date:  2014-03-06       Impact factor: 3.641

4.  Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.

Authors:  Jeffrey S Kennedy; Marc Gurwith; Cornelia L Dekker; Sharon E Frey; Kathryn M Edwards; Julie Kenner; Michael Lock; Cyril Empig; Shigeru Morikawa; Masayuki Saijo; Hiroyuki Yokote; Kevin Karem; Inger Damon; Mark Perlroth; Richard N Greenberg
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

5.  Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAs.

Authors:  Gary Hermanson; Sookhee Chun; Jiin Felgner; Xiaolin Tan; Jozelyn Pablo; Rie Nakajima-Sasaki; Douglas M Molina; Philip L Felgner; Xiaowu Liang; D Huw Davies
Journal:  Vaccine       Date:  2011-11-17       Impact factor: 3.641

Review 6.  Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.

Authors:  Stephen R Walsh; Raphael Dolin
Journal:  Expert Rev Vaccines       Date:  2011-08       Impact factor: 5.217

7.  Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.

Authors:  Richard N Greenberg; Edgar Turner Overton; David W Haas; Ian Frank; Mitchell Goldman; Alfred von Krempelhuber; Garth Virgin; Nicole Bädeker; Jens Vollmar; Paul Chaplin
Journal:  J Infect Dis       Date:  2012-12-07       Impact factor: 5.226

Review 8.  Killing a killer: what next for smallpox?

Authors:  Grant McFadden
Journal:  PLoS Pathog       Date:  2010-01-29       Impact factor: 6.823

9.  A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.

Authors:  Alfred von Krempelhuber; Jens Vollmar; Rolf Pokorny; Petra Rapp; Niels Wulff; Barbara Petzold; Amanda Handley; Lyn Mateo; Henriette Siersbol; Herwig Kollaritsch; Paul Chaplin
Journal:  Vaccine       Date:  2009-11-25       Impact factor: 3.641

10.  New smallpox vaccines for an ancient scourge.

Authors:  Sharon E Frey
Journal:  Mo Med       Date:  2014 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.